St. Jude buys Savacor
This article was originally published in The Gray Sheet
Executive Summary
$50 mil. purchase gives the cardiac giant HeartPOD, an implantable sensor designed todetect early symptoms of congestive heart failure and provide physicians with data to customize medication dosage. Savacor is pushing the device through clinical trials in the U.S. and internationally. The sensor is implanted in a patient's left atrial chamber where it monitors atrial pressure, body temperature and cardiac electrogram. St. Jude expects the transaction to close before January...
You may also be interested in...
St. Jude Sees Future ICD Market Growth With New Treatment Paradigms
St. Jude Medical expects its next-generation Unity electronics platform for use in both implantable cardioverter defibrillators and pacemakers to impact two-thirds of all revenue going forward
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.